Cargando…

The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis

OBJECTIVE: To investigate the optimal percutaneous coronary intervention (PCI) strategy in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease. METHODS: Trials that randomized patients with STEMI and multivessel coronary artery disease to immediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Meng-Jin, Tan, Jiang-Shan, Jiang, Wen-Yang, Gao, Xiao-Jin, Yang, Yue-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918769/
https://www.ncbi.nlm.nih.gov/pubmed/35295615
http://dx.doi.org/10.1177/20406223221078088
_version_ 1784668801969684480
author Hu, Meng-Jin
Tan, Jiang-Shan
Jiang, Wen-Yang
Gao, Xiao-Jin
Yang, Yue-Jin
author_facet Hu, Meng-Jin
Tan, Jiang-Shan
Jiang, Wen-Yang
Gao, Xiao-Jin
Yang, Yue-Jin
author_sort Hu, Meng-Jin
collection PubMed
description OBJECTIVE: To investigate the optimal percutaneous coronary intervention (PCI) strategy in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease. METHODS: Trials that randomized patients with STEMI and multivessel coronary artery disease to immediate multivessel PCI, staged multivessel PCI, or culprit-only PCI and prospective observational studies that investigated all-cause death were included. Random effect risk ratio (RR) and 95% confidence interval (CI) were calculated. RESULTS: A total of 13 randomized trials with 7627 patients and 21 prospective observational studies with 60311 patients were included. In the pairwise and network meta-analysis based on randomized trials, immediate or staged multivessel PCI was associated with a lower risk of long-term major adverse cardiac events (MACE; RR: 0.58; 95% CI: 0.45 to 0.74) than culprit-only PCI, which was mainly due to lower risks of myocardial infarction (RR: 0.67; 95% CI: 0.51 to 0.88) and revascularization (RR: 0.38; 95% CI: 0.28 to 0.51), without any significant difference in all-cause death (RR: 0.85; 95% CI: 0.69 to 1.04; I(2) = 0.0%). However, short-term outcomes were deficient in randomized trials. The results from real-world prospective observational studies suggested that staged multivessel PCI reduced long-term all-cause death (RR: 0.53; 95% CI: 0.39 to 0.71; I(2) = 15.6%), whereas immediate multivessel PCI increased short-term all-cause death (RR: 1.58; 95% CI: 1.22 to 2.05; I(2) = 43.8%) relative to culprit-only PCI. CONCLUSION: For patients in randomized trials, multivessel PCI in an immediate or staged procedure was preferred due to improvements in long-term outcomes. As a supplement, the results in real-world patients derived from prospective observational studies suggested that staged multivessel PCI was superior to immediate multivessel PCI. Therefore, staged multivessel PCI may be the optimal PCI strategy for patients with STEMI and multivessel coronary artery disease.
format Online
Article
Text
id pubmed-8918769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89187692022-03-15 The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis Hu, Meng-Jin Tan, Jiang-Shan Jiang, Wen-Yang Gao, Xiao-Jin Yang, Yue-Jin Ther Adv Chronic Dis Meta-Analysis OBJECTIVE: To investigate the optimal percutaneous coronary intervention (PCI) strategy in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease. METHODS: Trials that randomized patients with STEMI and multivessel coronary artery disease to immediate multivessel PCI, staged multivessel PCI, or culprit-only PCI and prospective observational studies that investigated all-cause death were included. Random effect risk ratio (RR) and 95% confidence interval (CI) were calculated. RESULTS: A total of 13 randomized trials with 7627 patients and 21 prospective observational studies with 60311 patients were included. In the pairwise and network meta-analysis based on randomized trials, immediate or staged multivessel PCI was associated with a lower risk of long-term major adverse cardiac events (MACE; RR: 0.58; 95% CI: 0.45 to 0.74) than culprit-only PCI, which was mainly due to lower risks of myocardial infarction (RR: 0.67; 95% CI: 0.51 to 0.88) and revascularization (RR: 0.38; 95% CI: 0.28 to 0.51), without any significant difference in all-cause death (RR: 0.85; 95% CI: 0.69 to 1.04; I(2) = 0.0%). However, short-term outcomes were deficient in randomized trials. The results from real-world prospective observational studies suggested that staged multivessel PCI reduced long-term all-cause death (RR: 0.53; 95% CI: 0.39 to 0.71; I(2) = 15.6%), whereas immediate multivessel PCI increased short-term all-cause death (RR: 1.58; 95% CI: 1.22 to 2.05; I(2) = 43.8%) relative to culprit-only PCI. CONCLUSION: For patients in randomized trials, multivessel PCI in an immediate or staged procedure was preferred due to improvements in long-term outcomes. As a supplement, the results in real-world patients derived from prospective observational studies suggested that staged multivessel PCI was superior to immediate multivessel PCI. Therefore, staged multivessel PCI may be the optimal PCI strategy for patients with STEMI and multivessel coronary artery disease. SAGE Publications 2022-03-10 /pmc/articles/PMC8918769/ /pubmed/35295615 http://dx.doi.org/10.1177/20406223221078088 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Meta-Analysis
Hu, Meng-Jin
Tan, Jiang-Shan
Jiang, Wen-Yang
Gao, Xiao-Jin
Yang, Yue-Jin
The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
title The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
title_full The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
title_fullStr The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
title_full_unstemmed The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
title_short The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
title_sort optimal percutaneous coronary intervention strategy for patients with st-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918769/
https://www.ncbi.nlm.nih.gov/pubmed/35295615
http://dx.doi.org/10.1177/20406223221078088
work_keys_str_mv AT humengjin theoptimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT tanjiangshan theoptimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT jiangwenyang theoptimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT gaoxiaojin theoptimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT yangyuejin theoptimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT humengjin optimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT tanjiangshan optimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT jiangwenyang optimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT gaoxiaojin optimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis
AT yangyuejin optimalpercutaneouscoronaryinterventionstrategyforpatientswithstsegmentelevationmyocardialinfarctionandmultivesseldiseaseapairwiseandnetworkmetaanalysis